← All trials
NCT03218592
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 28, 2017
- Primary completion
- Dec 25, 2018
- Completion date
- Mar 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 36
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of North Carolina at Chapel HillLead sponsor
- University of North Carolina at Chapel HillOverall official - principal investigator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.